Table 15 Summary of findings table for treatment with fremanezumab 675 mg quarterly subcutaneous injection compared with no treatment for prevention of chronic migraine

Reduction of monthly headache days follow up: 3 months

The mean reduction of monthly headache days was −2.5 days

The mean reduction of monthly headache days in the intervention group was 1.8 days fewer (2.4 fewer to 1.2 fewer)

–

⨁⨁⨁◯ MEDIUM^a

Treatment with Fremanezumab 675 mg reduces monthly headache days slightly compared to placebo.

Reduction of monthly acute treatment days follow up: 3 months

The mean reduction of monthly acute treatment days was −1.9 days

The mean reduction of monthly acute treatment days in the intervention group was 1.8 days fewer (2.4 fewer to 1.2 fewer)

–

⨁⨁⨁◯ MEDIUM^a

Treatment with Fremanezumab 675 mg reduces monthly acute treatment days slightly compared to placebo.

Improvement in functional HIT-6 score follow up: 3 months

The mean improvement in functional HIT-6 score was −4.5 points

The mean improvement in functional HIT-6 score in the intervention group was 1.9 points fewer (2.9 fewer to 0.9 fewer)

–

⨁⨁⨁◯ MEDIUM^a

Treatment with fremanezumab 675 mg improves functional HIT-6 score slightly compared to placebo.

At least 50% reduction of monthly headache days follow up: 3 months

181 per 1000

376 per 1000 (292 to 484)

RR 2.0820 (1.6167 to 2.6813)

⨁⨁⨁◯ MEDIUM^a

Treatment with Fremanezumab 675 mg results in at least 50% reduction of monthly headache days compared to placebo.

Serious adverse events follow up: 3 months

16 per 1000

8 per 1000 (2 to 32)

RR 0.4987 (0.1256 to 1.9792)

⨁⨁⨁◯ MEDIUM^a

Treatment with Fremanezumab 675 mg results in an unimportant reduction of serious adverse event occurrence compared to placebo.

Mortality follow up: 3 months

0 per 1000

< 1 per 1000

RR 2.9920 (0.1223 to 73.2174)

No deaths were observed with treatment with Fremanezumab 675 mg or placebo